Bob M. Moore II, Ph.D.

Bob M. Moore II, Ph.D.


Department of Pharmaceutical Sciences

The University of Tennessee Health Science Center
874 Union Avenue, Room 327D
Memphis, TN 38163
Tel: (901) 448-6085
Fax: (508) 448-6828
Email: Bob M. Moore


  • B.S. in Chemistry, Indiana State University, 1983
  • M.S. in Chemistry, Indiana State University, 1989
  • Ph.D. (Medicinal Chemistry), University of Kansas, 1995

Research Interests

Research in Dr. Moore's lab integrates synthetic organic chemistry, computational chemistry and biological assays aimed at developing new chemotherapeutic entities. The current areas of research include:

  1. Development of cannabinoid receptor (CB1 and CB2) agonist and antagonist.
  2. Development of novel therapies for combat causality care with emphasis on hemorrhagic shock and hemostasis.
  3. Development of GPRC directed anti-neoplastic agents.
  4. Combination drug therapies for the treatment of sepsis, stroke and ischemic brain conditions.

Representative Publications

  • Yu C, Moore BM, Kotchetkova I, Cordina RL, Celermajer DS. Causes of death in a contemporary adult congenital heart disease cohort. Heart. 2018 Apr 17. pii: heartjnl-2017-312777. doi: 10.1136/heartjnl-2017-312777. [Epub ahead of print] PubMed PMID: 29666178.
  • Abidi AH, Presley CS, Dabbous M, Tipton DA, Mustafa SM, Moore BM 2nd. Anti-inflammatory activity of cannabinoid receptor 2 ligands in primary hPDL fibroblasts. Arch Oral Biol. 2018 Mar;87:79-85. doi: 10.1016/j.archoralbio.2017.12.005. Epub 2017 Dec 6. PubMed PMID: 29274621.
  • Pressly JD, Mustafa SM, Adibi AH, Alghamdi S, Pandey P, Roy KK, Doerksen RJ, Moore BM Jr, Park F. Selective Cannabinoid 2 Receptor Stimulation Reduces Tubular Epithelial Cell Damage after Renal Ischemia-Reperfusion Injury. J Pharmacol Exp Ther. 2018 Feb;364(2):287-299. doi: 10.1124/jpet.117.245522. Epub 2017 Nov 29. PubMed PMID: 29187590; PubMed Central PMCID: PMC5774215.
  • Liu Y, McAfee SS, Guley NM, Del Mar N, Bu W, Heldt SA, Honig MG, Moore BM 2nd, Reiner A, Heck DH. Abnormalities in Dynamic Brain Activity Caused by Mild Traumatic Brain Injury Are Partially Rescued by the Cannabinoid Type-2 Receptor Inverse Agonist SMM-189. eNeuro. 2017 Aug 18;4(4). pii: ENEURO.0387-16.2017. doi: 10.1523/ENEURO.0387-16.2017. eCollection 2017 Jul-Aug. PubMed PMID: 28828401; PubMed Central PMCID: PMC5562300.
  • Moore BM, Ng HKB, Naoum C, Simmons L, Cartwright BL, Wilson MK, Ng MKC. Transcatheter Mitral Valve Replacement With a Novel Dual Stent Bioprosthesis. Circ Cardiovasc Interv. 2017 Jun;10(6). pii: e004841. doi: 10.1161/CIRCINTERVENTIONS.116.004841. PubMed PMID: 28566291.
  • Moore BM, Adams JT, Barakatt E. Outcomes Following a Vestibular Rehabilitation and Aerobic Training Program to Address Persistent Post-Concussion Symptoms. J Allied Health. 2016 Winter;45(4):e59-e68. PubMed PMID: 27915363.

View more references (pubmed link)